New beta-lactamases: a paradigm for the rapid response of bacterial evolution in the clinical setting.

Gian Maria Rossolini, Jean Denis Docquier

Research output: Contribution to journalArticlepeer-review

Abstract

Production of beta-lactamases is one of the most common mechanisms of bacterial resistance to beta-lactam antibiotics. In the clinical setting, the introduction of new classes of beta-lactams has invariably been followed by the emergence of new beta-lactamases capable of degrading them, as a paradigmatic example of rapid bacterial evolution under a rapidly changing selective environment. The scope of this article is to provide an overview on the recent evolution of beta-lactamase-mediated resistance among bacterial pathogens. Focus is on the mechanisms of evolution and dissemination of enzymes of greater clinical impact, including the extended-spectrum beta-lactamases, the AmpC-type beta-lactamases and the carbapenemases, which are currently responsible for emerging resistance to the most recent and powerful beta-lactams (the expanded-spectrum cephalosporins and the carbapenems) among major Gram-negative pathogens such as Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter.

Original languageEnglish
Pages (from-to)295-308
Number of pages14
JournalFuture Microbiology
Volume1
DOIs
Publication statusPublished - Oct 2006

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'New beta-lactamases: a paradigm for the rapid response of bacterial evolution in the clinical setting.'. Together they form a unique fingerprint.

Cite this